Peptidomics and Metabolomics Data from Hyperlipidemia Plasma Analysis

63 protein-derived peptide fragments and two unknown medium-molecular-weight compounds were identified in plasma samples from hyperlipidemia patients. The dataset was generated using a novel capillary electrophoresis–mass spectrometry platform with a 60-fold increased injection volume and detection limits of 10 pg/mL. Tomoaki Nitta authored this dataset, which was last updated on 2026-05-27.

Use Cases

• Identify potential peptide biomarkers for hyperlipidemia based on elevated levels of bradykinin, CLIP, and schizophrenia-related peptides.
• Validate analytical sensitivity for medium-molecular-weight compounds using the described CE–HRMS platform.
• Discover novel functional peptides from the 63 additional protein-derived peptide fragments.
• Characterize unknown medium-molecular-weight compounds found in patient plasma samples.

Strengths

• Detection limits of 10 pg/mL for peptides like bradykinin and ANP, indicating high sensitivity.
• Platform increased injection volume by 60-fold over standard methods.
• Dataset includes 63 identified peptide fragments and two unknown compounds.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect bias inherent to the specific patient cohort from figshare.

Provenance

Source

Tomoaki Nitta via figshare

Collection Method

Developed using capillary electrophoresis coupled with high-resolution mass spectrometry (CE–HRMS) with large-volume dual preconcentration.

Freshness

Last updated 2026-05-27 08:05:04; freshness should be verified.